Paul B. Koller

Oncology

1500 Duarte Rd
Duarte, CA 91010

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Journal: The New England journal of medicine

Published: September 02, 2026

Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia.

Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia.

Journal: Haematologica

Published: June 24, 2026

Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.

Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.

Journal: American journal of hematology

Published: May 29, 2026

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.

Journal: Blood advances

Published: May 01, 2026

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.

Journal: Blood advances

Published: May 01, 2026

Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation.

Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: January 30, 2026

Hypomethylating agents-venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT.

Hypomethylating agents-venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT.

Journal: Blood neoplasia

Published: December 19, 2025

FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience.

FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: November 20, 2025

The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden.

The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden.

Journal: American journal of hematology

Published: June 21, 2025

Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults ≥40 years old.

Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults ≥40 years old.

Journal: Leukemia & lymphoma

Published: May 21, 2025

Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment.

Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment.

Journal: Transplantation and cellular therapy

Published: May 07, 2025

Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis.

Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis.

Journal: Bone marrow transplantation

Published: April 30, 2025

Showing 1-12 of 73

Last Updated: 09/26/2026